Posted inBiotechnology
Posted inGenetics
StockWatch: Wall Street’s Leaders and Laggards of 2024
2024 had its dazzling moments, but, in the end, it was a year of treading water for biopharma stocks, judging…
Posted inBiotechnology
Discover Astellas’ differentiated approach to innovation partnerships
As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. If you are…
Posted inResearch
Clinical trials industry to grapple with new tech, additional uncertainty in 2025: Velocity Clinical Research CEO
Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies and…
Posted inBiotechnology
Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…
Posted inResearch
Clinical research company Javara lays off employees as part of restructuring
Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in…
Posted inBiotechnology
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit
A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…
Posted inBiotechnology
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…
Posted inBiotechnology
Apollomics, after giving up on GlycoMimetics’ leukemia therapy, posts drug’s latest phase 3 fail
The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…
Posted inBiotechnology
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…
Posted inBiotechnology
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…
